Novavax Inc on Monday reported late-stage data from its US-based clinical trial showing its vaccine is more than 90 percent effective against Covid-19 across a variety of variants of the virus.

The study of nearly 30,000 volunteers in the United States and Mexico puts Novavax on track to file for emergency authorisation in the United States and elsewhere in the third quarter of the year, the company said.

Novavax's protein-based Covid-19 vaccine candidate was more than 93 percent effective against the predominant variants of the coronavirus that have been...